(0.01%) 5 479.00 points
(-0.01%) 38 814 points
(0.05%) 19 932 points
(0.26%) $80.54
(1.04%) $2.82
(0.12%) $2 331.90
(-0.33%) $29.30
(-0.02%) $970.70
(0.04%) $0.932
(-0.12%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases...
Stats | |
---|---|
Šios dienos apimtis | 7 588 |
Vidutinė apimtis | 62 408 |
Rinkos kapitalizacija | 35.36M |
EPS | $-0.0462 ( Q3 | 2023-02-14 ) |
Last Dividend | $0.435 ( 2024-02-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.226 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0220 (4.60%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-08 | Meswani Parag V | Buy | 153 700 | Restricted Stock Units |
2022-02-08 | Nassif David W. | Buy | 546 500 | Restricted Stock Units |
2022-01-28 | Meswani Parag V | Sell | 0 | Common Stock |
2022-01-28 | Meswani Parag V | Sell | 15 625 | Stock Option (Right to Buy) |
2022-01-28 | Meswani Parag V | Sell | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 89 transactions |
Buy: 137 127 498 | Sell: 478 048 |
Tūris Koreliacija
Sio Gene Therapies Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sio Gene Therapies Inc. Koreliacija - Valiuta/Žaliavos
Sio Gene Therapies Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.980 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.620 |
Financial Reports:
No articles found.
Sio Gene Therapies Inc. Dividends
(Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.435 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.435 | 2024-02-08 |
Last Dividend | $0.435 | 2024-02-08 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.435 | -- |
Avg. Dividend % Per Year | 113.00% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2024 | $0.435 | 113.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Feb 2024 | $0.435 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.136 | 1.200 | -4.54 | -5.45 | [0 - 0.3] |
returnOnEquityTTM | -0.137 | 1.500 | -2.63 | -3.95 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 21.97 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 21.60 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 21.43 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 11.69 | 1.000 | 6.78 | 6.78 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.135 | 2.00 | -0.0451 | -0.0902 | [0 - 30] |
freeCashFlowPerShareTTM | -0.139 | 2.00 | -0.0697 | -0.139 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.005 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.49 | 1.000 | -0.656 | 0 | [1 - 100] |
returnOnEquityTTM | -0.137 | 2.50 | -1.692 | -3.95 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.139 | 2.00 | -0.0464 | -0.139 | [0 - 30] |
dividendYielPercentageTTM | 91.00 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.135 | 2.00 | -0.0451 | -0.0902 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0549 | 1.500 | -3.70 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.312 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sio Gene Therapies Inc.
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.